The Research Laboratory of Nabil Ahmed, MD

Dr. Nabil Ahmed is a physician-scientist engaged in translational research focusing on adoptive immunotherapy with gene-modified effector cells, to improve therapy for brain tumors.

Dr. Nabil Ahmed’s initial studies demonstrated that antigen-specific cytotoxic T cells could eradicate established brain tumors in medulloblastoma and Glioblastoma models.

Subsequent studies have demonstrated that the tumor-specific T cells, unlike conventional therapies, can effectively target the stem cell compartment in the tumor eradicating experimental tumors in animal models. Aligning with his primary interest is studying the role of T cells in creating a tumor niche and studying T cell migration to distant tumor sites in the brain. Dr. Nabil Ahmed therefore has experience in developing and translating cell and gene therapy studies to the clinic.

Clinical Trials

Currently, Dr. Nabil Ahmed is the principal investigator on 3 clinical trials targeting Glioblastoma and Osteosarcoma. All studies are FDA, IRB, RAC and IBC approved.

  • Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme (COGLI)
  • Study of Administration of CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM (HERT-GBM)
  • Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma (Learn More)

Program Participation

Dr. Nabil Ahmed is a member of the Center for Cell and Gene Therapy (CAGT) and  Dr. Helen Heslop’s research laboratory. He is also a member of the Brain Tumor Program.

Laboratory Members

Principal Investigator
Nabil Ahmed, MD

Staff Scientist
Sujith K. Joseph